1B-LSD

1. 2026-10-19issueIssued emergency
2. 2026-10-19issueIssued info_card
3. 2026-10-19issueIssued notice
4. 2026-09-07srcPharmacokinetics and Pharmacodynamics of Lysergic Acid Diethylamide Microdoses in Healthy Participants
5. 2026-09-07srcAcute Effects and Pharmacokinetics of LSD after Paroxetine or Placebo Pre-Administration in a Randomized, Double-Blind, Cross-Over Phase I Trial
6. 2026-09-07srcPsychedelics as Medicines: An Emerging New Paradigm
7. 2026-09-07srcReturn of the lysergamides. Part I: Analytical and behavioural characterization of 1-propionyl-d-lysergic acid diethylamide (1P-LSD)
8. 2026-09-07srcReturn of the lysergamides. Part II: Analytical and behavioural characterization of N6-allyl-6-norlysergic acid diethylamide (AL-LAD) and (2'S,4'S)-lysergic acid 2,4-dimethylazetidide (LSZ)
9. 2026-09-07srcReturn of the lysergamides. Part V: Analytical and behavioural characterization of 1-butanoyl-d-lysergic acid diethylamide (1B-LSD)
10. 2026-09-07srcReturn of the lysergamides. Part VI: Analytical and behavioural characterization of 1-cyclopropanoyl-d-lysergic acid diethylamide (1CP-LSD)
11. 2026-09-07srcAnalytical and behavioral characterization of 1-dodecanoyl-LSD (1DD-LSD)
12. 2026-09-07srcAnalytical and behavioral characterization of 1-hexanoyl-LSD (1H-LSD)
13. 2026-09-07srcAnalytical and Pharmacological Characterization of 1-(Furan-2-Carbonyl)-LSD (1F-LSD) and Comparison With 1-(Thiophene-2-Carbonyl)-LSD (1T-LSD)
14. 2026-09-07srcThe toxicity of psychedelic LSD derivatives: in silico approach for 1cP-LSD and analogs
15. 2026-09-07srcSafety pharmacology of acute LSD administration in healthy subjects
16. 2026-09-07srcPharmacokinetics and Pharmacodynamics of Lysergic Acid Diethylamide in Healthy Subjects
17. 2026-09-07srcCytochrome P450 enzymes contribute to the metabolism of LSD to nor-LSD and 2-oxo-3-hydroxy-LSD: Implications for clinical LSD use
18. 2026-09-07srcCrystal Structure of an LSD-Bound Human Serotonin Receptor
19. 2026-09-07srcStructure of a Hallucinogen-Activated Gq-Coupled 5-HT2A Serotonin Receptor
20. 2026-09-07srcPharmacological and biotransformation studies of 1-acyl-substituted derivatives of d-lysergic acid diethylamide (LSD)
21. 2026-09-07srcCorrelation between the potency of hallucinogens in the mouse head-twitch response assay and their behavioral and subjective effects in other species
22. 2026-09-07srcAdverse events associated with classic psychedelics and MDMA: a real-world population-based study using WHO pharmacovigilance database (VigiBase)
23. 2026-09-07srcTolerance and Cross-Tolerance among Psychedelic and Nonpsychedelic 5-HT2A Receptor Agonists in Mice
24. 2026-09-07srcAcute dose-dependent effects of lysergic acid diethylamide in a double-blind placebo-controlled study in healthy subjects
25. 2026-09-07srcPharmacological and non-pharmacological predictors of the LSD experience in healthy participants
26. 2026-09-07srcGenetic influence of CYP2D6 on pharmacokinetics and acute subjective effects of LSD in a pooled analysis
27. 2026-09-07srcA cluster of lysergic acid diethylamide (LSD) poisonings following insufflation of a white powder sold as cocaine
28. 2026-09-07srcPharmacokinetics and Concentration-Effect Relationship of Oral LSD in Humans
29. 2026-09-07srcThe pharmacology of lysergic acid diethylamide: a review
30. 2026-09-07srcPsychedelics
31. 2026-09-07srcSerotonin syndrome: is it a reason to avoid the use of tramadol with antidepressants?
32. 2026-09-07srcHallucinogenic Persisting Perception Disorder: A Case Series and Review of the Literature
33. 2026-09-07srcHallucinogen-Persisting Perception Disorder in a 16-Year-Old Adolescent
34. 2026-09-07src1B-LSD first market appearance August 2016
35. 2026-09-07src1B-LSD
36. 2026-09-04issueIssued emergency
37. 2026-09-04issueIssued info_card
38. 2026-09-04issueIssued notice
39. 2026-06-04proposal29 value proposals approved togetherone review action inferred from a shared reviewer and instant — the graph records one activity per proposal
40. 2026-06-04publicationPublication — backfill
41. 2026-04-28revisionRevision 1
42. 2026-04-28absenceSearched ClinicalTrials.gov for "1B-LSD lysergamide" — no results
43. 2026-04-28genGeneration — pipeline-v5pipeline-v5
44. 2026-04-28rungeneration run

The same entries, as forms: six forms.